BR112014009288A2 - formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona - Google Patents

formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona

Info

Publication number
BR112014009288A2
BR112014009288A2 BR112014009288A BR112014009288A BR112014009288A2 BR 112014009288 A2 BR112014009288 A2 BR 112014009288A2 BR 112014009288 A BR112014009288 A BR 112014009288A BR 112014009288 A BR112014009288 A BR 112014009288A BR 112014009288 A2 BR112014009288 A2 BR 112014009288A2
Authority
BR
Brazil
Prior art keywords
solid forms
thiomorpholinyl
dioxo
isoxazolyl
pyridinyl
Prior art date
Application number
BR112014009288A
Other languages
English (en)
Other versions
BR112014009288A8 (pt
Inventor
Thomas Andrew
Manns Joachim
Kammerer Michael
Wyttenbach Nicole
Grassmann Olaf
Dott Pascal
Schwitter Urs
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014009288A2 publication Critical patent/BR112014009288A2/pt
Publication of BR112014009288A8 publication Critical patent/BR112014009288A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona". a presente invenção refere-se a novas formas sólidas do composto da fórmula (i) (i), assim como solvatos, complexos de inclusão com outros compostos adequados, processos para a fabricação das mesmas, composições farmacêuticas contendo estas formas sólidas, e uso das mesmas como medicamentos.
BR112014009288A 2011-10-20 2012-10-17 formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona, seus usos e seus processos de preparação, e composições farmacêuticas BR112014009288A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185993 2011-10-20
PCT/EP2012/070522 WO2013057124A1 (en) 2011-10-20 2012-10-17 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone

Publications (2)

Publication Number Publication Date
BR112014009288A2 true BR112014009288A2 (pt) 2017-06-13
BR112014009288A8 BR112014009288A8 (pt) 2020-04-22

Family

ID=47019027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009288A BR112014009288A8 (pt) 2011-10-20 2012-10-17 formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona, seus usos e seus processos de preparação, e composições farmacêuticas

Country Status (20)

Country Link
US (2) US8785435B2 (pt)
EP (1) EP2768821B1 (pt)
JP (1) JP5918856B2 (pt)
KR (1) KR20140079503A (pt)
CN (1) CN103889971B (pt)
AR (1) AR088359A1 (pt)
AU (1) AU2012318294B2 (pt)
BR (1) BR112014009288A8 (pt)
CA (1) CA2850441A1 (pt)
DK (1) DK2768821T3 (pt)
ES (1) ES2606547T3 (pt)
HK (1) HK1193611A1 (pt)
HU (1) HUE030298T2 (pt)
IL (1) IL231532A0 (pt)
MX (1) MX341492B (pt)
PL (1) PL2768821T3 (pt)
RU (1) RU2618524C2 (pt)
SG (1) SG11201401591WA (pt)
SI (1) SI2768821T1 (pt)
WO (1) WO2013057124A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
KR20200044906A (ko) * 2017-08-28 2020-04-29 유니버시티 오브 매릴랜드, 발티모어 기분장애를 위한 신규한 감마 아미노부티르산 타입 a 수용체 모듈레이터
JP7478676B2 (ja) 2018-06-13 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー Ｇａｂａ ａ ａｌｐｈａ５ ｐａｍとしての新規イソオキサゾリルエーテル誘導体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE352505C (de) 1918-03-01 1922-04-27 Metallbank Verfahren zur Verarbeitung von Salmiakschlacken
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6262098B1 (en) 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
CA2388593A1 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
US7820705B2 (en) 2004-05-14 2010-10-26 Irm Llc Compounds and compositions as PPAR modulators
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1802566B1 (en) 2004-10-01 2008-11-26 F. Hoffmann-Roche AG Hexafluoroisopropanol substituted ether derivatives
WO2006044617A1 (en) 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006095822A1 (ja) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. スルホンアミド化合物およびその医薬
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007009275A1 (de) 2005-07-20 2007-01-25 Prospective Concepts Ag Pneumatische kissenstrukturen
EP1931661B1 (en) 2005-09-19 2008-11-19 F.Hoffmann-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
EP1937674A1 (en) 2005-10-11 2008-07-02 F.Hoffmann-La Roche Ag Isoxazole derivatives
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007062997A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
WO2007071476A1 (en) * 2005-12-20 2007-06-28 International Business Machines Corporation Method, system and computer program for distributing software products based on an e-mail service
AU2007212126B2 (en) 2006-02-03 2012-07-19 Eli Lilly And Company Compounds and methods for modulating FX-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
RS53877B1 (en) 2007-12-04 2015-08-31 F. Hoffmann-La Roche Ag. IZOKSAZOL-PYRIDINE DERIVATIVES
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives

Also Published As

Publication number Publication date
HK1193611A1 (zh) 2014-09-26
MX2014004678A (es) 2014-05-28
NZ622215A (en) 2016-06-24
RU2618524C2 (ru) 2017-05-04
EP2768821A1 (en) 2014-08-27
US20130172329A1 (en) 2013-07-04
SG11201401591WA (en) 2014-05-29
US20140329806A1 (en) 2014-11-06
CN103889971B (zh) 2016-08-31
JP5918856B2 (ja) 2016-05-18
EP2768821B1 (en) 2016-11-16
ES2606547T3 (es) 2017-03-24
SI2768821T1 (sl) 2017-01-31
US8785435B2 (en) 2014-07-22
US8975397B2 (en) 2015-03-10
DK2768821T3 (en) 2017-01-23
CN103889971A (zh) 2014-06-25
HUE030298T2 (en) 2017-04-28
AR088359A1 (es) 2014-05-28
PL2768821T3 (pl) 2017-05-31
CA2850441A1 (en) 2013-04-25
BR112014009288A8 (pt) 2020-04-22
WO2013057124A1 (en) 2013-04-25
AU2012318294A1 (en) 2013-05-09
MX341492B (es) 2016-08-23
KR20140079503A (ko) 2014-06-26
RU2014118968A (ru) 2015-11-27
JP2014530832A (ja) 2014-11-20
IL231532A0 (en) 2014-04-30
AU2012318294B2 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CY1116439T1 (el) Τριαζολοπυριδινες
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
CO6480975A2 (es) Mimetico de smac
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201170772A1 (ru) Органические соединения
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201390381A1 (ru) Триазиноксадиазолы
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201591195A1 (ru) Новые хинолоновые производные
PH12015501609A1 (en) Phenicol antibacterials
BR112015018504A2 (pt) moduladores de flap
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
TW200738627A (en) Trialkylsilyl-indoles
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.